Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 1
1986 1
1987 1
1988 7
1989 3
1990 19
1991 7
1992 2
1993 13
1994 10
1995 9
1996 17
1997 13
1998 9
1999 17
2000 17
2001 12
2002 11
2003 13
2004 16
2005 7
2006 5
2007 8
2008 17
2009 11
2010 7
2011 11
2012 5
2013 5
2014 8
2015 10
2016 6
2017 5
2018 4
2019 2
2020 1
2021 2
2022 5
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

304 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer.
Madan RA, Bilusic M, Stein MN, Donahue RN, Arlen PM, Karzai F, Plimack E, Wong YN, Geynisman DM, Zibelman M, Mayer T, Strauss J, Chen G, Rauckhorst M, McMahon S, Couvillon A, Steinberg S, Figg WD, Dahut WL, Schlom J, Gulley JL. Madan RA, et al. Oncologist. 2023 Jul 5;28(7):642-e561. doi: 10.1093/oncolo/oyad058. Oncologist. 2023. PMID: 37134294 Free PMC article. Clinical Trial.
The median time to treatment failure after a median potential follow-up of 46.7 months was, 4.5 months (range 2-70) for flutamide alone vs. 6.9 months (2.5-40; P = .38) with flutamide+vaccine. ...Antigen-specific responses were similar in both arms (58% of patients …
The median time to treatment failure after a median potential follow-up of 46.7 months was, 4.5 months (range 2-70) for flutamide alo …
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter D, Yip S, Zhang AY, Zielinski RR, Davis ID; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Sweeney CJ, et al. Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3. Lancet Oncol. 2023. PMID: 36990608 Clinical Trial.
Participants were randomly assigned (1:1), using a centralised web-based system and stratified by volume of disease, planned use of concurrent docetaxel and bone antiresorptive therapy, comorbidities, and study site, to receive testosterone suppression plus oral enzalutamide (160 …
Participants were randomly assigned (1:1), using a centralised web-based system and stratified by volume of disease, planned use of concurre …
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study.
Iguchi T, Tamada S, Kato M, Yasuda S, Machida Y, Ohmachi T, Ishii K, Iwata H, Yamamoto S, Kanamaru T, Morimoto K, Hase T, Tashiro K, Harimoto K, Deguchi T, Adachi T, Iwamoto K, Takegaki Y, Nakatani T. Iguchi T, et al. Int J Clin Oncol. 2020 Mar;25(3):486-494. doi: 10.1007/s10147-019-01554-3. Epub 2019 Sep 28. Int J Clin Oncol. 2020. PMID: 31564004 Clinical Trial.
BACKGROUND: Before the androgen target therapy era, flutamide was widely used for castration-resistant prostate cancer in Japan. ...Enzalutamide provided superior prostate-specific antigen progression-free survival compared with flutamide (HR 0.29; 95% CI 0.15-0.54; …
BACKGROUND: Before the androgen target therapy era, flutamide was widely used for castration-resistant prostate cancer in Japan. ...E …
Flutamide in unresectable pancreatic adenocarcinoma: a randomized, double-blind, placebo-controlled trial.
Negi SS, Agarwal A, Chaudhary A. Negi SS, et al. Invest New Drugs. 2006 May;24(3):189-94. doi: 10.1007/s10637-005-3536-2. Invest New Drugs. 2006. PMID: 16133790 Clinical Trial.
PURPOSE: To evaluate the impact of flutamide on survival of patients with unresectable pancreatic cancer. ...This small sample sized study, failed to demonstrate a dramatic effect on survival with the use of flutamide. Median overall survival was 151 days with the u …
PURPOSE: To evaluate the impact of flutamide on survival of patients with unresectable pancreatic cancer. ...This small sample sized …
Comparison between "5% minoxidil plus 2% flutamide" solution vs. "5% minoxidil" solution in the treatment of androgenetic alopecia.
Faghihi G, Iraji F, Siadat AH, Saber M, Jelvan M, Hoseyni MS. Faghihi G, et al. J Cosmet Dermatol. 2022 Oct;21(10):4447-4453. doi: 10.1111/jocd.14788. Epub 2022 Feb 18. J Cosmet Dermatol. 2022. PMID: 35152531 Clinical Trial.
Minoxidil and finasteride are regarded as the first-line treatments with antiandrogens and flutamide are considered as the alternative choices. In the current study, we evaluated the efficacy of combination therapy with topical 2%flutamide plus 5% minoxidil vs. %5 m …
Minoxidil and finasteride are regarded as the first-line treatments with antiandrogens and flutamide are considered as the alternativ …
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study).
Iguchi T, Tamada S, Kato M, Yasuda S, Yamasaki T, Nakatani T. Iguchi T, et al. BMC Cancer. 2019 Apr 11;19(1):339. doi: 10.1186/s12885-019-5526-3. BMC Cancer. 2019. PMID: 30971225 Free PMC article. Clinical Trial.
The expected results of this study will be that enzalutamide is superior to flutamide in terms of PSA response. A longer time to disease progression with enzalutamide over flutamide may translate to better overall survival. However, flutamide may be more acce …
The expected results of this study will be that enzalutamide is superior to flutamide in terms of PSA response. A longer time to dise …
Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial.
Jones CU, Pugh SL, Sandler HM, Chetner MP, Amin MB, Bruner DW, Zietman AL, Den RB, Leibenhaut MH, Longo JM, Bahary JP, Rosenthal SA, Souhami L, Michalski JM, Hartford AC, Amin PP, Roach M 3rd, Yee D, Efstathiou JA, Rodgers JP, Feng FY, Shipley WU. Jones CU, et al. Int J Radiat Oncol Biol Phys. 2022 Feb 1;112(2):294-303. doi: 10.1016/j.ijrobp.2021.08.031. Epub 2021 Sep 1. Int J Radiat Oncol Biol Phys. 2022. PMID: 34481017 Free PMC article. Clinical Trial.
Patients were stratified by PSA, tumor grade, and surgical versus clinical nodal staging. ADT was flutamide with either goserelin or leuprolide for 4 months. Prostate RT (66.6 Gy) was started after 2 months. ...
Patients were stratified by PSA, tumor grade, and surgical versus clinical nodal staging. ADT was flutamide with either goserelin or …
Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group.
Fosså SD, Slee PH, Brausi M, Horenblas S, Hall RR, Hetherington JW, Aaronson N, de Prijck L, Collette L. Fosså SD, et al. J Clin Oncol. 2001 Jan 1;19(1):62-71. doi: 10.1200/JCO.2001.19.1.62. J Clin Oncol. 2001. PMID: 11134196 Clinical Trial.
RESULTS: There was no difference between the groups in median TTP (prednisone, 3.4 months; flutamide, 2.3 months) or overall survival (prednisone, 10.6 months; flutamide, 11.2 months). In the prednisone group, 56% of the patients experienced a subjective response, c …
RESULTS: There was no difference between the groups in median TTP (prednisone, 3.4 months; flutamide, 2.3 months) or overall survival …
Flutamide administration at 500 mg daily has similar effects on serum testosterone to 750 mg daily.
Murphy JC, Srinivas S, Terris MK. Murphy JC, et al. J Androl. 2004 Jul-Aug;25(4):630-4. doi: 10.1002/j.1939-4640.2004.tb02834.x. J Androl. 2004. PMID: 15223852 Free article. Clinical Trial.
Testosterone and PSA levels show a dose-dependent response to flutamide monotherapy. Loss of libido and erectile dysfunction occurred in all 3 treatment groups, with a trend toward worsening sexual function with higher flutamide dosing, but this trend did not reach …
Testosterone and PSA levels show a dose-dependent response to flutamide monotherapy. Loss of libido and erectile dysfunction occurred …
[Finasteride and flutamide in the treatment of hirsutism].
Falsetti L, De Fusco D, Rosina B. Falsetti L, et al. Minerva Ginecol. 1997 Oct;49(10):463-8. Minerva Ginecol. 1997. PMID: 9463180 Clinical Trial. Italian.
Finasteride was administered per os to 40 women at the dose of 5 mg/die; flutamide per os to 40 women at the dose of 250 mg twice daily. Both drugs were employed for 6 consecutive months. RESULTS: Both finasteride and flutamide significantly reduced the F.G. score a …
Finasteride was administered per os to 40 women at the dose of 5 mg/die; flutamide per os to 40 women at the dose of 250 mg twice dai …
304 results

Searches related to "flutamide"